Botox vs Dermal Filler: What Is the Difference? — Aesthetic Decision Guide

The Core Difference: Muscle Activity or Volume?

The two most commonly confused treatments in medical aesthetics are not interchangeable — they complement each other. A short answer first:

• Botox temporarily softens the movement of a muscle. Dynamic wrinkles caused by facial expressions — horizontal forehead lines, the "11" between the brows, crow's feet — are its domain.
• Dermal filler adds volume beneath the skin or creates contour. Static lines related to volume loss over time, hollows (mid-face, under-eyes, nasolabial folds) and contouring needs (lips, cheekbones, jawline) are its domain.

In many patients, both are relevant. The answer to "which should I have first?" depends on the source of your concern. If a line appears when you make an expression and disappears at rest, the route is botox. If a hollow, a line or a loss of fullness remains on a still face, the route is dermal filler.

Both Botox and hyaluronic acid filler treatments at Nis Clinic are planned by Op. Dr. İbrahim Meyzin with reference to plastic surgery anatomy.

Botox: The Neurotoxin That Relaxes Facial Muscles

Botox is a brand name that has entered everyday language. The active substance is botulinum toxin type A, purified from the Clostridium botulinum bacterium. When injected in small doses into a target muscle beneath the skin, it blocks the signal travelling from the nerve ending to the muscle (acetylcholine release). The muscle relaxes temporarily, the overlying skin smooths, and expression-related lines soften.

The effect lasts 3–6 months; the body gradually inactivates the toxin, nerve-to-muscle communication returns, and the treatment is repeated.

Principal brands legally used in the European Union and Northern Cyprus (TRNC):

• Botox® (Allergan): The reference product in the sector, with the longest clinical history of use.
• Dysport® (Galderma/Ipsen): Smaller molecule size, spreads slightly wider from the injection point — may be preferred for hyperhidrosis or a broad forehead. Dosage units differ from Botox (approximately 1:2.5–3).
• Xeomin® (Merz): A "pure neurotoxin" formulation containing no accessory proteins. Data suggest a reduced risk of antibody development with frequent long-term use.
• Azzalure® (Ipsen): The European market parallel line of Dysport for cosmetic indications.

Brand differences are exaggerated in marketing. In practice, the choice of product is decided with your clinician based on the target area, your previous botox history and the desired spread. CE-approved product, cold-chain supply, visible batch number and expiry date on the vial — these are details every patient has the right to ask about.

Dermal Filler: Hyaluronic Acid Gel for Volume and Contour

Dermal filler is the general term for a semi-fluid material injected beneath the skin to restore volume, fill lines or refine facial contour. The large majority of fillers used in medical aesthetics today contain hyaluronic acid (HA).

Hyaluronic acid is a natural component of the skin; it retains water and gives tissue elasticity and volume. Production declines with age. HA fillers are manufactured from cross-linked molecules produced in the laboratory. The degree of cross-linking and the elasticity modulus (G′) determine the gel's viscosity, the depth at which it is placed, and how long it remains in tissue.

• High G′ (dense gel): Deep supraperiosteal (above bone) placement for structural support areas such as cheekbones, chin and jawline.
• Mid G′: Mid-depth (subdermal) placement for areas such as nasolabial folds and marionette lines.
• Low G′ (fluid gel): Intradermal or superficial placement for delicate areas such as under-eyes, fine lines and the lip vermillion border.

HA fillers are temporary; longevity ranges from 6 to 18 months depending on the area. Their most important property is reversibility: an unsatisfactory outcome or a rare complication can be dissolved in a controlled manner using hyaluronidase enzyme. Permanent fillers (silicone, PMMA) are not recommended by current international expert society consensus — the risks of granuloma, late-onset nodules and inability to remove are substantially greater than with HA.

Common HA filler families on the market: Juvederm (Allergan), Restylane (Galderma), Teoxane RHA, Belotero (Merz). Brand selection alone does not determine outcomes; correct region-to-gel matching and the clinician's anatomical knowledge are the deciding factors.

Region-by-Region Decision Matrix

The answer to "which should I have?" depends on the area of concern and the character of the line — dynamic or static. The table below summarises our region-based approach at Nis Clinic.

Practical summary: Moving from the top of the face downwards, the boundary roughly works as follows — the upper third (forehead, between brows, eye area) is primarily a botox zone; the mid-face and mouth area are primarily a filler zone; the lower face and jaw area are where the two are planned together.

Why Combination Is the Rule, Not the Exception

After the age of 35, cases involving purely botox or purely filler concerns are uncommon. A forehead line that deepens with expression alongside a descent of mid-face support is a frequently encountered combination. When only one treatment is chosen, the result often produces a feeling of "my face looks rested but still tired" — because the missing component is still there.

The rationale for combination treatment:

• Forehead + between brows: Botox softens dynamic lines. If deep static lines have developed over time, superficial HA (fluid gel) is applied over them to smooth the surface.
• Nasolabial folds + cheekbones: Adding filler only to the nasolabial fold often misses the source of the problem. Deepening of nasolabial folds is frequently linked to loss of mid-face support; restoring cheekbone support reduces a significant part of the fold. Residual lines are then addressed with localised correction.
• Chin tip: If the mentalis muscle is overactive, an orange-peel texture appears on the chin — botox addresses this. However, if chin projection is insufficient, structural support is added with filler. Both can be performed in the same session or within the same treatment plan.
• Lips: Lip volume and contour are the domain of filler. But if "barcode" lines are present on the upper lip, low-dose botox is added to reduce the pressure of muscle movement.
• Full-face rejuvenation: Botox (upper face) + mid-face/jawline filler + mesotherapy or platelet-rich plasma (PRP) (skin quality) — this trio delivers outcomes in the mid-forties that a single type of injectable cannot achieve alone.

Our approach at Nis Clinic: The face is assessed as a whole during consultation. Rather than "what would you like done?", the better starting question is "what bothers you most when you look in the mirror?" Procedures that are not necessary are not recommended; when they are necessary, they are not compressed into a single appointment but planned in stages.

Duration, Risks and Cost Differences

The practical aspects of both treatments are critical for most patients when making a decision. A concise comparison:

Duration of Effect

• Botox: 3–6 months (typically at the lower end of the range at first session; with regular treatment the duration of effect may extend)
• HA filler: 6–18 months depending on the area. The most mobile area — lips — lasts 6–9 months; the longest-lasting is dense supraperiosteal placement at 12–18 months

Onset of Effect

• Botox: First signs appear at 2–3 days, full effect at 10–14 days. Final assessment is made at day 14.
• HA filler: Visual change is immediate. However, in the first 24–72 hours swelling makes the area appear fuller than the final result; the settled outcome becomes apparent 2 weeks later.

Recovery

• Botox: Zero downtime. You can return to social activities on the same day. Avoid lying down, rubbing the area or strenuous exercise for the first 4 hours.
• HA filler: 1–3 days of swelling, sometimes bruising for 7–10 days. Avoid saunas, intense exercise and hot environments for the first 2 weeks. If you have an important event, plan treatment at least 2 weeks beforehand.

Risk Profile

• Botox risks: Mild and temporary. The main ones are: bruising at the injection site, transient headache, and rarely eyelid drooping (ptosis) or brow asymmetry (related to incorrect placement or dosing). The effect cannot be reversed early, but because it is time-limited, it fades naturally within 3–4 months.
• Filler risks: Expected side effects are mild (swelling, bruising). The rare but serious complication is vascular occlusion — cessation of blood flow when gel enters a vessel or compresses one from the outside. If not treated promptly, skin necrosis and in rare cases vision loss can occur. The highest-risk areas are glabella, nasal bridge, nasolabial folds and tear trough. Management: emergency dissolution of gel with hyaluronidase enzyme.

At Nis Clinic, hyaluronidase is kept in cold-chain stock on every treatment day. A clinic that performs filler without stocking hyaluronidase has closed off half its safety window. This preparation is not a promise that nothing will go wrong; it is being ready when something does.

Costs (2026 — Nis Clinic approximate ranges)

Botox is priced per-area in packages; filler is priced by millilitre and area. Prices are confirmed after consultation; there are no hidden charges.

First-Time Treatment and Age-Based Approach

"I have never had this done — which should I start with?" is one of the most common questions at consultation. The practical answer:

A first treatment is usually botox — three reasons:

1. The effect is not irreversible. Even in the case of an incorrect placement or higher dose, the effect fades naturally within 3–4 months.
2. You gain experience. A patient having treatment for the first time learns in practice about their own facial expression patterns and how much softening they prefer.
3. Lower complication profile. The vascular occlusion risk associated with filler has no equivalent with botox.

A little more caution with filler:

Filler creates a visible change that persists for 2–4 weeks in the treated area (even though it is reversible with hyaluronidase). Starting conservatively at the first session — for example, 1 ml for lips or 1 ml for cheekbones — is the right approach. The "overfilled" look generally develops in patients where excessive volume is applied at the first session or where top-up intervals are shortened.

Age ranges:

• Ages 25–30 (preventive botox / "baby botox"): No static lines have formed yet; dynamic expressions are beginning to repeat frequently. Low-dose botox slows the deepening of lines over the years. Filler is not usually necessary at this age; excessive early filler can cause tissue stretching over time and a "puffy face" appearance.
• Ages 30–40 (standard cosmetic): Botox becomes more common for dynamic wrinkles. Selective filler may begin for early, mild volume loss in the mid-face.
• Ages 40–50 (combination period): Botox + targeted filler (cheekbones, nasolabial folds, tear trough) is the most frequently prescribed pair. Mesotherapy or PRP is added for skin quality.
• Ages 50+ (comprehensive plan): Filler alone is often insufficient; in patients where skin laxity has become prominent, surgical alternatives (facelift, blepharoplasty) are considered alongside injectables. Medical aesthetics is not a tool for indefinitely delaying surgery; when the right time arrives, surgery offers a more durable solution.

Age figures are not rigid; biological age and individual expectations matter more than chronological age. A slender, low body-weight patient of 35 may show greater volume loss than a fuller-faced patient of 45. The decision is made at examination.

Why Nis Clinic? Clinical Standards Beyond a Decision Guide

Botox and dermal filler are performed in Northern Cyprus (TRNC) across dozens of settings — from beauty salons to chain clinics, dermatologists to plastic surgeons. Being an informed patient is valuable; choosing the right practitioner is the step that actually determines the outcome.

Nis Clinic's standards centre on three points:

• Plastic surgery anatomy. Botox requires knowledge of the facial muscle map; filler requires knowledge of the vascular and nerve anatomy of the face. Op. Dr. İbrahim Meyzin is a Specialist in Plastic, Reconstructive and Aesthetic Surgery (Cyprus Turkish Medical Association (CTMA), Registration No. 969). He performs all treatments personally; the "technician supervised by a doctor" model does not apply at our clinic.
• Hyaluronidase emergency stock. Preparedness for vascular occlusion is a clinical necessity. Available in cold-chain storage on every treatment day. Our team follows a standardised protocol for early recognition and emergency management of vascular occlusion.
• Transparent pricing and product traceability. The botox or filler brand, batch number and expiry date are shown on the day of treatment; on request, the product barcode is added to your patient file. No hidden charges. Pricing is per-area or per-millilitre, confirmed after consultation. A 14-day follow-up — and for botox, a touch-up — is included in the package.

If you are travelling from abroad, an initial assessment can be carried out via Zoom or WhatsApp. For patients who wish to combine a stay in Northern Cyprus with a medical aesthetics appointment, our medical tourism packages cover transfer and accommodation. Complementary skin-quality treatments such as PRP and dermaroller (microneedling) can also be incorporated into the same plan.

Use the appointment page to book a consultation, or reach us directly via the contact page.